- call +1-201-465-4211
- email sales@mrinsights.biz
Combination antibody therapy is receiving higher recognition from the oncological branch of medical science research. This is primarily due to the growing use of combination therapy over single drug treatments such as radiation or chemotherapy. In addition, companies that manufacture combination antibody drugs are actively focusing on developing superior drugs that will deliver standout results. Factors such as encouraging government policies, growing concerns over higher cancer prevalence worldwide, and increasing research and development activities coupled with heavier investments are expected to boost the overall market growth in the near future. Likewise, healthy R&D pipelines are leading towards higher product offerings and also propelling the growth of global combination antibody therapy market to a significant extent.
Scope of the Report:
This report studies the Combination Antibody Therapy market status and outlook of Global and major regions, from angles of players, countries, product types and end industries; this report analyzes the top players in global market, and splits the Combination Antibody Therapy market by product type and applications/end industries.
The first and foremost reason for fueling the growth of the chemotherapy/antibody segment is the rise in the rates of cancer across the globe. Cancer is the second leading cause of death globally after cardiovascular disease. The proportion of deaths around the world due to cancer has increased remarkably in the last few years.
The global Combination Antibody Therapy market is valued at xx million USD in 2017 and is expected to reach xx million USD by the end of 2023, growing at a CAGR of xx% between 2017 and 2023.
The Asia-Pacific will occupy for more market share in following years, especially in China, also fast growing India and Southeast Asia regions.
North America, especially The United States, will still play an important role which cannot be ignored. Any changes from United States might affect the development trend of Combination Antibody Therapy.
Europe also play important roles in global market, with market size of xx million USD in 2017 and will be xx million USD in 2023, with a CAGR of xx%.
Market Segment by Companies, this report covers
Biogen
Roche Holdings
Seattle Genetics
Amgen
Bristol-Myers Squibb
Eli Lilly
Novartis
Sanofi
Celgene
Genmab
Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
Chemotherapy/Antibody
Antibody/Antibody
Conjugated Antibodies
Bispecific Antibodies
Market Segment by Applications, can be divided into
Hospitals
Cancer Research Institutes
Clinics
ASCs
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
Table of Contents
1 Combination Antibody Therapy Market Overview
1.1 Product Overview and Scope of Combination Antibody Therapy
1.2 Classification of Combination Antibody Therapy by Types
1.2.1 Global Combination Antibody Therapy Revenue Comparison by Types (2017-2023)
1.2.2 Global Combination Antibody Therapy Revenue Market Share by Types in 2017
1.2.3 Chemotherapy/Antibody
1.2.4 Antibody/Antibody
1.2.5 Conjugated Antibodies
1.2.6 Bispecific Antibodies
1.3 Global Combination Antibody Therapy Market by Application
1.3.1 Global Combination Antibody Therapy Market Size and Market Share Comparison by Applications (2013-2023)
1.3.2 Hospitals
1.3.3 Cancer Research Institutes
1.3.4 Clinics
1.3.5 ASCs
1.4 Global Combination Antibody Therapy Market by Regions
1.4.1 Global Combination Antibody Therapy Market Size (Million USD) Comparison by Regions (2013-2023)
1.4.1 North America (USA, Canada and Mexico) Combination Antibody Therapy Status and Prospect (2013-2023)
1.4.2 Europe (Germany, France, UK, Russia and Italy) Combination Antibody Therapy Status and Prospect (2013-2023)
1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Combination Antibody Therapy Status and Prospect (2013-2023)
1.4.4 South America (Brazil, Argentina, Colombia) Combination Antibody Therapy Status and Prospect (2013-2023)
1.4.5 Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Combination Antibody Therapy Status and Prospect (2013-2023)
1.5 Global Market Size of Combination Antibody Therapy (2013-2023)
2 Manufacturers Profiles
2.1 Biogen
2.1.1 Business Overview
2.1.2 Combination Antibody Therapy Type and Applications
2.1.2.1 Product A
2.1.2.2 Product B
2.1.3 Biogen Combination Antibody Therapy Revenue, Gross Margin and Market Share (2016-2017)
2.2 Roche Holdings
2.2.1 Business Overview
2.2.2 Combination Antibody Therapy Type and Applications
2.2.2.1 Product A
2.2.2.2 Product B
2.2.3 Roche Holdings Combination Antibody Therapy Revenue, Gross Margin and Market Share (2016-2017)
2.3 Seattle Genetics
2.3.1 Business Overview
2.3.2 Combination Antibody Therapy Type and Applications
2.3.2.1 Product A
2.3.2.2 Product B
2.3.3 Seattle Genetics Combination Antibody Therapy Revenue, Gross Margin and Market Share (2016-2017)
2.4 Amgen
2.4.1 Business Overview
2.4.2 Combination Antibody Therapy Type and Applications
2.4.2.1 Product A
2.4.2.2 Product B
2.4.3 Amgen Combination Antibody Therapy Revenue, Gross Margin and Market Share (2016-2017)
2.5 Bristol-Myers Squibb
2.5.1 Business Overview
2.5.2 Combination Antibody Therapy Type and Applications
2.5.2.1 Product A
2.5.2.2 Product B
2.5.3 Bristol-Myers Squibb Combination Antibody Therapy Revenue, Gross Margin and Market Share (2016-2017)
2.6 Eli Lilly
2.6.1 Business Overview
2.6.2 Combination Antibody Therapy Type and Applications
2.6.2.1 Product A
2.6.2.2 Product B
2.6.3 Eli Lilly Combination Antibody Therapy Revenue, Gross Margin and Market Share (2016-2017)
2.7 Novartis
2.7.1 Business Overview
2.7.2 Combination Antibody Therapy Type and Applications
2.7.2.1 Product A
2.7.2.2 Product B
2.7.3 Novartis Combination Antibody Therapy Revenue, Gross Margin and Market Share (2016-2017)
2.8 Sanofi
2.8.1 Business Overview
2.8.2 Combination Antibody Therapy Type and Applications
2.8.2.1 Product A
2.8.2.2 Product B
2.8.3 Sanofi Combination Antibody Therapy Revenue, Gross Margin and Market Share (2016-2017)
2.9 Celgene
2.9.1 Business Overview
2.9.2 Combination Antibody Therapy Type and Applications
2.9.2.1 Product A
2.9.2.2 Product B
2.9.3 Celgene Combination Antibody Therapy Revenue, Gross Margin and Market Share (2016-2017)
2.10 Genmab
2.10.1 Business Overview
2.10.2 Combination Antibody Therapy Type and Applications
2.10.2.1 Product A
2.10.2.2 Product B
2.10.3 Genmab Combination Antibody Therapy Revenue, Gross Margin and Market Share (2016-2017)
3 Global Combination Antibody Therapy Market Competition, by Players
3.1 Global Combination Antibody Therapy Revenue and Share by Players (2013-2018)
3.2 Market Concentration Rate
3.2.1 Top 5 Combination Antibody Therapy Players Market Share
3.2.2 Top 10 Combination Antibody Therapy Players Market Share
3.3 Market Competition Trend
4 Global Combination Antibody Therapy Market Size by Regions
4.1 Global Combination Antibody Therapy Revenue and Market Share by Regions
4.2 North America Combination Antibody Therapy Revenue and Growth Rate (2013-2018)
4.3 Europe Combination Antibody Therapy Revenue and Growth Rate (2013-2018)
4.4 Asia-Pacific Combination Antibody Therapy Revenue and Growth Rate (2013-2018)
4.5 South America Combination Antibody Therapy Revenue and Growth Rate (2013-2018)
4.6 Middle East and Africa Combination Antibody Therapy Revenue and Growth Rate (2013-2018)
5 North America Combination Antibody Therapy Revenue by Countries
5.1 North America Combination Antibody Therapy Revenue by Countries (2013-2018)
5.2 USA Combination Antibody Therapy Revenue and Growth Rate (2013-2018)
5.3 Canada Combination Antibody Therapy Revenue and Growth Rate (2013-2018)
5.4 Mexico Combination Antibody Therapy Revenue and Growth Rate (2013-2018)
6 Europe Combination Antibody Therapy Revenue by Countries
6.1 Europe Combination Antibody Therapy Revenue by Countries (2013-2018)
6.2 Germany Combination Antibody Therapy Revenue and Growth Rate (2013-2018)
6.3 UK Combination Antibody Therapy Revenue and Growth Rate (2013-2018)
6.4 France Combination Antibody Therapy Revenue and Growth Rate (2013-2018)
6.5 Russia Combination Antibody Therapy Revenue and Growth Rate (2013-2018)
6.6 Italy Combination Antibody Therapy Revenue and Growth Rate (2013-2018)
7 Asia-Pacific Combination Antibody Therapy Revenue by Countries
7.1 Asia-Pacific Combination Antibody Therapy Revenue by Countries (2013-2018)
7.2 China Combination Antibody Therapy Revenue and Growth Rate (2013-2018)
7.3 Japan Combination Antibody Therapy Revenue and Growth Rate (2013-2018)
7.4 Korea Combination Antibody Therapy Revenue and Growth Rate (2013-2018)
7.5 India Combination Antibody Therapy Revenue and Growth Rate (2013-2018)
7.6 Southeast Asia Combination Antibody Therapy Revenue and Growth Rate (2013-2018)
8 South America Combination Antibody Therapy Revenue by Countries
8.1 South America Combination Antibody Therapy Revenue by Countries (2013-2018)
8.2 Brazil Combination Antibody Therapy Revenue and Growth Rate (2013-2018)
8.3 Argentina Combination Antibody Therapy Revenue and Growth Rate (2013-2018)
8.4 Colombia Combination Antibody Therapy Revenue and Growth Rate (2013-2018)
9 Middle East and Africa Revenue Combination Antibody Therapy by Countries
9.1 Middle East and Africa Combination Antibody Therapy Revenue by Countries (2013-2018)
9.2 Saudi Arabia Combination Antibody Therapy Revenue and Growth Rate (2013-2018)
9.3 UAE Combination Antibody Therapy Revenue and Growth Rate (2013-2018)
9.4 Egypt Combination Antibody Therapy Revenue and Growth Rate (2013-2018)
9.5 Nigeria Combination Antibody Therapy Revenue and Growth Rate (2013-2018)
9.6 South Africa Combination Antibody Therapy Revenue and Growth Rate (2013-2018)
10 Global Combination Antibody Therapy Market Segment by Type
10.1 Global Combination Antibody Therapy Revenue and Market Share by Type (2013-2018)
10.2 Global Combination Antibody Therapy Market Forecast by Type (2018-2023)
10.3 Chemotherapy/Antibody Revenue Growth Rate (2013-2023)
10.4 Antibody/Antibody Revenue Growth Rate (2013-2023)
10.5 Conjugated Antibodies Revenue Growth Rate (2013-2023)
10.6 Bispecific Antibodies Revenue Growth Rate (2013-2023)
11 Global Combination Antibody Therapy Market Segment by Application
11.1 Global Combination Antibody Therapy Revenue Market Share by Application (2013-2018)
11.2 Combination Antibody Therapy Market Forecast by Application (2018-2023)
11.3 Hospitals Revenue Growth (2013-2018)
11.4 Cancer Research Institutes Revenue Growth (2013-2018)
11.5 Clinics Revenue Growth (2013-2018)
11.6 ASCs Revenue Growth (2013-2018)
12 Global Combination Antibody Therapy Market Size Forecast (2018-2023)
12.1 Global Combination Antibody Therapy Market Size Forecast (2018-2023)
12.2 Global Combination Antibody Therapy Market Forecast by Regions (2018-2023)
12.3 North America Combination Antibody Therapy Revenue Market Forecast (2018-2023)
12.4 Europe Combination Antibody Therapy Revenue Market Forecast (2018-2023)
12.5 Asia-Pacific Combination Antibody Therapy Revenue Market Forecast (2018-2023)
12.6 South America Combination Antibody Therapy Revenue Market Forecast (2018-2023)
12.7 Middle East and Africa Combination Antibody Therapy Revenue Market Forecast (2018-2023)
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Data Source
List of Tables and Figures
Figure Combination Antibody Therapy Picture
Table Product Specifications of Combination Antibody Therapy
Table Global Combination Antibody Therapy and Revenue (Million USD)
ProactiveWe manage our resources 24/7 to identify issues and address them before they become problems
Quality & ReliabilityWe are committed to providing reliable and highly accurate data with an excellent quality control system
Global Outreach6 Major regions and 40+ countries level analysis accomplished
Competitive PricingOur pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery
